Edwards Lifesciences Says EARLY TAVR Trial Showed That Within The First 6-Months, 26.2% Of Patients In The Clinical Surveillance Arm Converted To AVR With Many Presenting Progressive Or Advanced Symptoms; In The 12-Month Follow-Up Period After...

Benzinga · Oct 28 23:15

Edwards Lifesciences Says EARLY TAVR Trial Showed That Within The First 6-Months, 26.2% Of Patients In The Clinical Surveillance Arm Converted To AVR With Many Presenting Progressive Or Advanced Symptoms; In The 12-Month Follow-Up Period After Randomization, The Rate Of Conversion To AVR Was 47.2%

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Edwards Lifesciences Says EARLY TAVR Trial Showed That Within The First 6-Months, 26.2% Of Patients In The Clinical Surveillance Arm Converted To AVR With Many Presenting Progressive Or Advanced Symptoms; In The 12-Month Follow-Up Period After...

Edwards Lifesciences Says EARLY TAVR Trial Showed That Within The First 6-Months, 26.2% Of Patients In The Clinical Surveillance Arm Converted To AVR With Many Presenting Progressive Or Advanced Symptoms; In The 12-Month Follow-Up Period After Randomization, The Rate Of Conversion To AVR Was 47.2%

Risk Disclaimer